Taken together, K12 CAR-T cells exhibited better activity in vitro than scFvCD7 CAR-T cells and may hold promise for the treatment of CD7-positive relapsed/refractory T cell leukemia/lymphoma and AML. This evidence concerns the gene CD7 and lymphoma.